Skip to main content
Clinical Trials/NL-OMON25639
NL-OMON25639
Recruiting
Not Applicable

Title *Vaccinations in Immunocompromised Patients, Rabies Antibody Response after pre exposure prophylaxis - The VIPRAR study

The International Society of Travel Medicine (ISTM)0 sites50 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
The International Society of Travel Medicine (ISTM)
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
The International Society of Travel Medicine (ISTM)

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18\-70 years old with a chronic inflammatory condition requiring treatment with one of the following drugs: adalimumab, infliximab, etanercept, golimumab, certolizumab, methotrexate, azathioprine, 6\-mercaptopurine, thioguanine, steroids, tacrolimus or mycophenolic acid.
  • Being naïve to rabies vaccines
  • Anticipated travel to a rabies\-endemic country in the future

Exclusion Criteria

  • Diagnosis of one of the following
  • oPrimary immune deficiency disorder
  • oActive malignancy
  • oAnyone who received chemotherapy or anti\-CD20 in the past 2 years.
  • oHemophilic disorder precluding intramuscular vaccination
  • o(Functional) asplenia
  • oAllergy to any of the components of the rabies vaccine.
  • Not able or willing to consent
  • Using other immunosuppressive agents than the mentioned

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Vaccinations in persons with a condition affecting the immune system: paramount and paradox.ImmunocompromisedHIVImmunosuppressive medicationStem cell transplantationOrgan transplantationrheumatic diseasesinflammatory bowel diseaseVaccineVaccinationHepatitis A vaccinePneumococcal vaccineImmunogenicity
NL-OMON24856Amsterdam UMC (locatie AMC)570
Recruiting
Not Applicable
Vaccinations in the Immunocompromised population: paramount and paradox.Immunocompromising conditionsimpaired immune system1002766510021879
NL-OMON56421Academisch Medisch Centrum980
Active, not recruiting
Phase 1
Immunization of immunosuppressed patients – Knowledge, practices and serological responseImmunoresponse on pneumococcal vaccination of kidney transplant recipients in immunomodulatory therapy or patients with end stage renal disease.MedDRA version: 21.0Level: LLTClassification code 10076412Term: Chronic kidney disease stage 5System Organ Class: 100000004857MedDRA version: 21.1Level: LLTClassification code 10069594Term: Pneumococcal immunizationSystem Organ Class: 100000004865MedDRA version: 20.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 100000004865Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2016-004123-23-DKDepartment of Infectious Diseases, Odense University Hospital200
Active, not recruiting
Phase 1
Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity.Patients with IgG-deficiencyTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2012-004486-41-SEKarolinska University Hospital, Huddinge, Sweden20
Completed
Not Applicable
Covid-19 Vaccination in Patients with Inflammatory Bowel DiseasesInflammatory Bowel Diseases
DRKS00025694Medizinische Hochschule Hannover23